-
Febrasgo Position Statement
Hyperprolactinemia in women: diagnostic approach
Rev Bras Ginecol Obstet. 2024;46:e-FPS04
Summary
Febrasgo Position StatementHyperprolactinemia in women: diagnostic approach
Rev Bras Ginecol Obstet. 2024;46:e-FPS04
-
Febrasgo Position Statement
Hyperprolactinemia in women: treatment
Rev Bras Ginecol Obstet. 2024;46:e-FPS05
Summary
Febrasgo Position StatementHyperprolactinemia in women: treatment
Rev Bras Ginecol Obstet. 2024;46:e-FPS05
-
Febrasgo Position Statement
Use of hormones and risk of venous thromboembolism
Rev Bras Ginecol Obstet. 2024;46:e-FPS02
Summary
Febrasgo Position StatementUse of hormones and risk of venous thromboembolism
Rev Bras Ginecol Obstet. 2024;46:e-FPS02
Views228See moreKey points
•The risk of venous thromboembolism (VTE) is not increased in women using long-acting reversible contraceptive methods (LARCs) with progestogens.
•Oral contraceptives with levonorgestrel or norgestimate confer half the risk of VTE compared to oral contraceptives containing desogestrel, gestodene or drospirenone.
•Progestogen-only pills do not confer an increased risk of VTE.
•Women using transdermal contraceptive patches and combined oral contraceptives (COCs) are at an approximately eight times greater risk of VTE than non-users of hormonal contraceptives (HCs), corresponding to 9.7 events per 10,000 women/years.
•Vaginal rings increase the risk of VTE by 6.5 times compared to not using HC, corresponding to 7.8 events per 10,000 women/years.
•Several studies have demonstrated an increased risk of VTE in transgender individuals receiving hormone therapy (HT).
•Hormone therapy during menopause increases the risk of VTE by approximately two times, and this risk is increased by obesity, thrombophilia, age over 60 years, surgery and immobilization.
•The route of estrogen administration, the dosage and type of progestogen associated with estrogen may affect the risk of VTE in the climacteric.
•Combined estrogen-progesterone therapy increases the risk of VTE compared to estrogen monotherapy.
•Postmenopausal HT increases the risk of thrombosis at atypical sites.
-
Febrasgo Position Statement
Vulvovaginitis in pregnant women
Rev Bras Ginecol Obstet. 2024;46:e-FPS03
Summary
Febrasgo Position StatementVulvovaginitis in pregnant women
Rev Bras Ginecol Obstet. 2024;46:e-FPS03
Views227See moreKey points
• The balanced vaginal microbiome is the main factor defending the vaginal environment against infections. Lactobacilli play a key role in this regard, maintaining the vaginal pH within the normal range (3.8 to 4.5).
•Hormonal and immune adaptations resulting from pregnancy influence changes in the vaginal microbiome during pregnancy.
•An altered vaginal microbiome predisposes to human immunodeficiency virus (HIV) infection.
•Bacterial vaginosis is the main clinical expression of an imbalanced vaginal microbiome.
•Vulvovaginal candidiasis depends more on the host’s conditions than on the etiological agent.
•Trichomonas vaginalis is a protozoan transmitted during sexual intercourse.
•The use of probiotics is not approved for use in pregnant women.
-
Febrasgo Position Statement
Breech birth care: Number 1 – 2024
Rev Bras Ginecol Obstet. 2024;46:e-rbgofps1
Summary
Febrasgo Position StatementBreech birth care: Number 1 – 2024
Rev Bras Ginecol Obstet. 2024;46:e-rbgofps1
-
Febrasgo Position Statement
Challenges of breast cancer screening: Number 9 – September 2023
Rev Bras Ginecol Obstet. 2023;45(9):551-554
Summary
Febrasgo Position StatementChallenges of breast cancer screening: Number 9 – September 2023
Rev Bras Ginecol Obstet. 2023;45(9):551-554
-
Febrasgo Position Statement
Trauma and pregnancy: Number 10 – October 2023
Rev Bras Ginecol Obstet. 2023;45(10):622-631
Summary
Febrasgo Position StatementTrauma and pregnancy: Number 10 – October 2023
Rev Bras Ginecol Obstet. 2023;45(10):622-631
-
Febrasgo Position Statement
Operative vaginal delivery: Number 7 – July 2023
Rev Bras Ginecol Obstet. 2023;45(7):422-434
Summary
Febrasgo Position StatementOperative vaginal delivery: Number 7 – July 2023
Rev Bras Ginecol Obstet. 2023;45(7):422-434
Search
Search in:
Tag Cloud
breast (42) breast cancer (42) breast neoplasms (95) Cesarean section (72) endometriosis (66) infertility (56) Maternal mortality (43) menopause (82) obesity (58) postpartum period (40) pregnancy (225) Pregnancy complications (99) Prenatal care (68) prenatal diagnosis (50) Prevalence (41) Quality of life (51) risk factors (94) ultrasonography (79) urinary incontinence (40) women's health (48)